The Parkinson's Foundation announced on Monday that it has awarded community grants, valued at more than USD1.5m, for Parkinson's programmes in 38 states across the country.
For 2019, the Foundation's grant will focus on three areas including: programmes that provide a service for underserved PD communities, initiatives that reach the newly diagnosed and clinical trial education and participation that reach those under-represented in the PD community.
The USD1.5m in community grants range from a minimum of USD5,000 to a maximum of USD25,000 per grant application.
Through the community grants, the Foundation will support local health, wellness and educational programmes that address unmet needs in the Parkinson's disease (PD) community. The programmes include wellness, dance, music therapy and educational programmes that can help people with Parkinson's live better with the disease.
Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the US. It is associated with a progressive loss of motor control such as shaking or tremor at rest and lack of facial expression, as well as non-motor symptoms like depression and anxiety. The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure.
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD